


Welcome [\[Sign In\]](#)To track stocks & more, [Register](#)

## Financial News

Enter symbol(s)

Basic

[Symbol Lookup](#)

## Top Stories

- [Stocks End Up Despite Volatile Oil Prices](#) - Associated Press (5:38 pm)
- [Crude Oil Prices Surpass \\$50 Per Barrel](#) - Associated Press (6:00 pm)
- [Consumer Confidence Dips on Job Worries](#) - Associated Press (4:31 pm)
- [Motorola Eliminating 1,000 Jobs Worldwide](#) - Associated Press (4:45 pm)

[More...](#)

## Press Release

Source: ProteoTech Inc

## ProteoTech Receives Phase I SBIR Award From the National Institute of Health to Develop Small Molecule Therapeutics for the Treatment of Systemic AA Amyloidosis

Friday September 24, 8:01 am ET

KIRKLAND, Wash., Sept 24 /PRNewswire/ -- ProteoTech ("Proteoglycan Technologies") Inc today announced that it has received a Phase I Small Business Innovative Research (SBIR) award from the National Institute of Arthritis and Musculoskeletal and Skin Disorders branch of the NIH. The \$264,984 award to ProteoTech (with principal investigator, Alan D. Snow, Ph.D., President & CSO) will fund a 9-month study to further develop a number of novel small molecule therapeutics that ProteoTech scientists have identified as potent inhibitors for a variety of different amyloid diseases, including systemic AA amyloidosis. Systemic AA amyloidosis occurs in a small subset of patients with rheumatoid arthritis or other inflammatory diseases, in which AA amyloid fibril accumulation occurs in systemic organs, including heart, kidney, liver and gastrointestinal tract. The amyloid accumulation causes major organ failure, and currently there are no effective treatments to effectively reduce or eliminate the harmful AA amyloid deposits that deposit in systemic organs.

- (Logo: <http://www.newscom.com/cgi-bin/prnh/20020220/SFW009LOGO>)

This is ProteoTech's 10th SBIR award during the last 5 years from the National Institute of Health, with over \$6.5 million in funding acquired to develop new therapeutics and diagnostics for amyloid diseases, including Alzheimer's and systemic AA amyloidosis.

ProteoTech is rated #1 in the State of Washington in receiving SBIR awards from the National Institute of Health.

ProteoTech is a world leader in the research and development of disease-modifying therapeutics derived from proteoglycan and amyloid technologies to treat human amyloid diseases. ProteoTech has identified novel small molecule therapeutics for the treatment of Alzheimer's, Parkinson's, type 2 diabetes and systemic amyloidosis. Exebryl(TM)-1, the Company's breakthrough therapeutic for Alzheimer's, is in late pre-clinical development and has been proven to markedly reduce brain amyloid plaque deposits and dramatically reverse memory impairment in older Alzheimer's transgenic animals. ProteoTech is currently completing a Preferred Series B private financing round. Interested investors should contact Alan D. Snow, Ph.D., President & CSO at [snow@proteotech.com](mailto:snow@proteotech.com) for further information.

Source: ProteoTech Inc

 [Email Story](#) [Set News Alert](#) [Print Story](#)